RECRUITING

Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study

Conditions

Chronic Subdural Hematoma chronic subdural hematoma (CSDH)middle meningeal artery embolization (MMAE)

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to test in moderately symptomatic chronic subdural hematoma (CSDH) patients if middle meningeal artery embolization (MMAE) can be used as an alternative to conventional open surgery. The main questions it aims to answer are: * Compared to open conventional surgery, does MMAE reduce the need for rescue surgery or deaths? * What is the safety of MMAE and conventional open surgery in these patients? Participants will be asked to: * Share their medical history and undergo physical examinations * Have blood drawn * Have CT scans of the head * Answer questionnaires * Undergo MMAE or conventional open surgery * Provide information about possible adverse events Researchers will compare participants in the MMAE group with those in the conventional open surgery group to see if there is a reduced need for rescue surgery or deaths and evaluate safety.

Official Title

Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study

Quick Facts

Study Start:2024-11-01

Study Completion:2028-09

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06347796

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:40 Years to 90 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Age 40-90 years inclusively. 2. Per CT of the head, (one of the following): Unilateral convexity CSDH measuring at least 10 mm in thickness OR Bilateral CSDH if only one side is considered for treatment and the contralateral side is asymptomatic and \&lt; 5 mm in thickness. 3. CSDH at least 2/3 isodense or hypodense, verified on axial CT slice used to measure the thickness of the qualifying CSDH. 4. Qualifying baseline head CT performed within the 7 days prior to randomization. 5. Able to undergo assigned treatment within 48 hours after randomization. 6. Patient or legally authorized representative agrees to be randomized, and provides written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization.	1. Secondary cause apart from trauma for the qualifying SDH, such as an underlying vascular abnormality or tumor. 2. Tentorial or interhemispheric SDH. 3. Previous craniotomy for the treatment of CSDH if the craniotomy exceeds 7 cm at the maximal dimension on the baseline CT. 4. mRS of 5 or higher. 5. Emergent surgical evacuation such as open craniotomy, burr hole drainage, or Subdural Evacuating Port System (SEPS) is required for the patient. 6. Unable to withhold all antiplatelet agents or OACs for the first 7 days after randomization. 7. Indication that withdrawal of care will be implemented for the qualifying SDH. 8. Prior surgical treatment for CSDH if the surgery is less than 30 days prior to randomization. 9. On tranexamic acid. 10. Platelet count of \&lt;100,000 per microliter refractory to transfusion. 11. Coagulopathy that cannot be corrected to an INR of ≤1.5. 12. Known contraindications to angiography. 13. Known intolerance to occlusion procedures. 14. Known vascular anatomy (small artery size) or blood flow (high vascular resistance peripheral to the feeding arteries) that precludes catheter placement or embolic agent (Embosphere Microspheres or CONTOUR particles) injection. 15. Known presence of collateral vessel pathways potentially endangering normal territories or cranial nerves during embolization. 16. Known large diameter arteriovenous shunt, i.e., where the blood does not pass through an arterial/capillary/venous transition but directly from an artery to a vein or presence of patent extra-to-intracranial anastomoses (where study embolization devices could pass directly into the internal carotid artery, vertebral artery, or intracranial vasculature) that cannot be addressed with coil embolization. 17. Patient has a known active systemic infection or sepsis. 18. Patient is pregnant, planning to become pregnant, or lactating. 19. Life expectancy of less than 6 months due to comorbid terminal conditions. 20. Concurrent participation in another research protocol for investigation of an experimental therapy. 21. Known or suspected to not be able to comply with the study protocol. 22. No measurable deficit on the Timed Up and Go \[TUG\], Aphasia Severity Rating \[ASR\], or MRC.

Inclusion Criteria

Exclusion Criteria

1. Age 40-90 years inclusively.
2. Per CT of the head, (one of the following): Unilateral convexity CSDH measuring at least 10 mm in thickness OR Bilateral CSDH if only one side is considered for treatment and the contralateral side is asymptomatic and \&lt; 5 mm in thickness.
3. CSDH at least 2/3 isodense or hypodense, verified on axial CT slice used to measure the thickness of the qualifying CSDH.
4. Qualifying baseline head CT performed within the 7 days prior to randomization.
5. Able to undergo assigned treatment within 48 hours after randomization.
6. Patient or legally authorized representative agrees to be randomized, and provides written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization.

1. Secondary cause apart from trauma for the qualifying SDH, such as an underlying vascular abnormality or tumor.
2. Tentorial or interhemispheric SDH.
3. Previous craniotomy for the treatment of CSDH if the craniotomy exceeds 7 cm at the maximal dimension on the baseline CT.
4. mRS of 5 or higher.
5. Emergent surgical evacuation such as open craniotomy, burr hole drainage, or Subdural Evacuating Port System (SEPS) is required for the patient.
6. Unable to withhold all antiplatelet agents or OACs for the first 7 days after randomization.
7. Indication that withdrawal of care will be implemented for the qualifying SDH.
8. Prior surgical treatment for CSDH if the surgery is less than 30 days prior to randomization.
9. On tranexamic acid.
10. Platelet count of \&lt;100,000 per microliter refractory to transfusion.
11. Coagulopathy that cannot be corrected to an INR of ≤1.5.
12. Known contraindications to angiography.
13. Known intolerance to occlusion procedures.
14. Known vascular anatomy (small artery size) or blood flow (high vascular resistance peripheral to the feeding arteries) that precludes catheter placement or embolic agent (Embosphere Microspheres or CONTOUR particles) injection.
15. Known presence of collateral vessel pathways potentially endangering normal territories or cranial nerves during embolization.
16. Known large diameter arteriovenous shunt, i.e., where the blood does not pass through an arterial/capillary/venous transition but directly from an artery to a vein or presence of patent extra-to-intracranial anastomoses (where study embolization devices could pass directly into the internal carotid artery, vertebral artery, or intracranial vasculature) that cannot be addressed with coil embolization.
17. Patient has a known active systemic infection or sepsis.
18. Patient is pregnant, planning to become pregnant, or lactating.
19. Life expectancy of less than 6 months due to comorbid terminal conditions.
20. Concurrent participation in another research protocol for investigation of an experimental therapy.
21. Known or suspected to not be able to comply with the study protocol.
22. No measurable deficit on the Timed Up and Go \[TUG\], Aphasia Severity Rating \[ASR\], or MRC.

Contacts and Locations

Study Contact

Jessica Spahn

CONTACT

409-266-8859

jlspahn@utmb.edu

Roberto Garcia

CONTACT

409-772-3182

robgarci@utmb.edu

Study Locations (Sites)

University of Texas Medical Branch

Galveston, Texas, 77555

United States

Collaborators and Investigators

Sponsor: The University of Texas Medical Branch, Galveston

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-11-01

Study Completion Date2028-09

Study Record Updates

Study Start Date2024-11-01

Study Completion Date2028-09

Terms related to this study

Keywords Provided by Researchers

chronic subdural hematoma (CSDH)
middle meningeal artery embolization (MMAE)

Additional Relevant MeSH Terms

Chronic Subdural Hematoma